Bold Brain never invested in platform companies.  The Founding partners were of the opinion years ago that a platform with many applications for radiologists to pick from would not provide the clinical and technological guidance that the radiologist needed to implement AI.

“Pharmaceutical giant Bayer said it plans to deprioritize its investment in AI platform company Blackford Analysis as part of a general move away from the platform business. Bayer is also winding down its investment in Calantic Digital Solutions, the digital platform company it formed in 2022. The move is a stunning turnaround for Blackford, which was founded in 2010 and was the first and perhaps most prominent of the digital AI platform companies.”

Read the full article here: https://theimagingwire.com/2025/09/07/investment-in-ai-platform-company-blackford/